165 related articles for article (PubMed ID: 11033582)
1. Some statistical considerations on the FDA draft guidance for individual bioequivalence.
Hsuan FC
Stat Med; 2000 Oct; 19(20):2879-84. PubMed ID: 11033582
[TBL] [Abstract][Full Text] [Related]
2. Population and individual bioequivalence: lessons from real data and simulation studies.
Zariffa NM; Patterson SD
J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
[TBL] [Abstract][Full Text] [Related]
3. PhRMA perspective on population and individual bioequivalence.
Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
[TBL] [Abstract][Full Text] [Related]
4. An individual bioequivalence criterion: regulatory considerations.
Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
[TBL] [Abstract][Full Text] [Related]
5. Case studies, practical issues and observations on population and individual bioequivalence.
Zariffa NM; Patterson SD; Boyle D; Hyneck M
Stat Med; 2000 Oct; 19(20):2811-20. PubMed ID: 11033577
[TBL] [Abstract][Full Text] [Related]
6. A small sample confidence interval approach to assess individual bioequivalence.
Hyslop T; Hsuan F; Holder DJ
Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
[TBL] [Abstract][Full Text] [Related]
7. Individual bioequivalence revisited.
Chen ML; Lesko LJ
Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
[TBL] [Abstract][Full Text] [Related]
8. Kullback-Leibler divergence for evaluating bioequivalence.
Dragalin V; Fedorov V; Patterson S; Jones B
Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies.
Tothfalusi L; Endrenyi L
Int J Clin Pharmacol Ther; 2001 Apr; 39(4):162-6. PubMed ID: 11332872
[TBL] [Abstract][Full Text] [Related]
10. Prescribability and switchability of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
[TBL] [Abstract][Full Text] [Related]
11. On statistical power for average bioequivalence testing under replicated crossover designs.
Wan H; Chow SC
J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
[TBL] [Abstract][Full Text] [Related]
12. Individual bioequivalence testing under 2x3 designs.
Chow SC; Shao J; Wang H
Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806
[TBL] [Abstract][Full Text] [Related]
13. Current Regulatory Standpoint on Evaluating the Bioequivalence of Different Classes of Generic Drugs - Is the Evaluation in the Right Direction?
Micheal F; Sayana M; Motial BM
Curr Drug Metab; 2019; 20(10):835-844. PubMed ID: 31589117
[TBL] [Abstract][Full Text] [Related]
14. The bioequivalence of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
[TBL] [Abstract][Full Text] [Related]
15. Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products.
Patterson SD; Zariffa NM; Montague TH; Howland K
Eur J Clin Pharmacol; 2001 Nov; 57(9):663-70. PubMed ID: 11791897
[TBL] [Abstract][Full Text] [Related]
16. Tests for individual and population bioequivalence based on generalized p-values.
McNally RJ; Iyer H; Mathew T
Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
[TBL] [Abstract][Full Text] [Related]
17. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
Hauschke D; Steinijans VW
Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
[TBL] [Abstract][Full Text] [Related]
18. The bootstrap in bioequivalence studies.
Pigeot I; Hauschke D; Shao J
J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
[TBL] [Abstract][Full Text] [Related]
19. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
20. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
Lechat P
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
